Clinical Trial Update: Trial Twice Daily Application of LEO 124249 Ointment 30 mg/g in Treatment of Mild to Moderate Inverse Psoriasis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating twice-daily application of LEO 124249 ointment 30 mg/g for mild to moderate inverse psoriasis has completed. The study, cond…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inverse Psoriasis

Drugs mentioned

• LEO 124249 ointment

Snippet

Sponsor: LEO Pharma | Conditions: Inverse Psoriasis | Phase 2 | Status: COMPLETED